Berlucchi Marco, Salsi Daria, Valetti Luisa, Parrinello Giovanni, Nicolai Piero
Department of Pediatric Otorhinolaryngology, Spedali Civili, Brescia, Italy.
Pediatrics. 2007 Jun;119(6):e1392-7. doi: 10.1542/peds.2006-1769. Epub 2007 May 28.
We evaluated the efficacy of mometasone furoate aqueous nasal spray in decreasing adenoid size and reducing the severity of chronic nasal obstruction symptoms in children affected by adenoidal hypertrophy.
Sixty children were recruited in a 2-stage, randomized, placebo-controlled trial. All patients complained of chronic nasal obstruction symptoms, and nasal endoscopy showed >75% choanal obstruction attributable to adenoid pads. In the first stage, 30 patients (group A) underwent mometasone treatment (50 microg per nostril per day) for 40 days, and 30 children (group B) received placebo. In the second stage, at the end of the first 40-day treatment period, patients in group A who showed subjective and objective clinical improvement were divided into 2 subgroups; group A1 (11 children) received topical intranasal steroid treatment on alternate days for the first 2 weeks per month, whereas group A2 (10 children) continued daily mometasone treatment for the first 2 weeks per month. After 3 months, all children were reassessed.
Fifty-seven children completed the study according to the protocol. After the first treatment period, the severity of symptoms and adenoid size decreased for 21 patients (77.7%) in group A. No improvement was observed in the placebo group. After 3 months of additional therapy, group A2 patients demonstrated a more-pronounced reduction in adenoid size compared with group A1 patients. No statistically significant change in symptoms was identified. Mometasone treatment was well tolerated by all patients.
Mometasone furoate aqueous nasal spray may be considered useful in decreasing adenoid pad size and the severity of symptoms related to adenoidal hypertrophy. Children with adenoidal hypertrophy that is not associated with tonsillar hypertrophy should be considered for intranasal mometasone treatment before surgery is planned.
我们评估了糠酸莫米松水鼻喷雾剂在减小腺样体大小及减轻腺样体肥大患儿慢性鼻塞症状严重程度方面的疗效。
60名儿童被纳入一项两阶段、随机、安慰剂对照试验。所有患者均有慢性鼻塞症状,鼻内镜检查显示后鼻孔阻塞>75%是由腺样体引起。在第一阶段,30名患者(A组)接受糠酸莫米松治疗(每侧鼻孔每天50微克),持续40天,30名儿童(B组)接受安慰剂治疗。在第二阶段,在第一个40天治疗期结束时,A组中主观和客观临床症状有改善的患者被分为2个亚组;A1组(11名儿童)在每月的前2周隔天接受鼻内局部类固醇治疗,而A2组(10名儿童)在每月的前2周继续每日使用糠酸莫米松治疗。3个月后,对所有儿童进行重新评估。
57名儿童按方案完成了研究。在第一个治疗期后,A组21名患者(77.7%)的症状严重程度和腺样体大小有所减轻。安慰剂组未观察到改善。在额外治疗3个月后,与A1组患者相比,A2组患者的腺样体大小减小更为明显。症状方面未发现有统计学意义的变化。所有患者对糠酸莫米松治疗耐受性良好。
糠酸莫米松水鼻喷雾剂在减小腺样体大小及减轻与腺样体肥大相关症状的严重程度方面可能是有用的。对于腺样体肥大但不伴有扁桃体肥大的儿童,在计划手术前应考虑鼻内使用糠酸莫米松治疗。